L
LequteMan
Guest
People infected with the #Eboa virus could in the near future gain access to TKM-Ebola, a drug that's been held up in Phase I clinical trials by the US Food & Drug Administration, Business Insider says.
This came after the FDA modified the full clinical hold placed on the drug, which enables it to be administered to people sick with the virus.
Excerpt:
Here's what management is said in its 4:45 p.m. ET press release: "[Tekmira] today announced that the U.S. Food & Drug Administration (FDA) has verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola Investigational New Drug Application (IND) to a partial clinical hold. This action enables the potential use of TKM-Ebola in individuals infected with Ebola virus."
"We are pleased that the FDA has considered the risk-reward of TKM-Ebola for infected patients," said Tekmira CEO Mark Murray. "We have been closely watching the Ebola virus outbreak and its consequences, and we are willing to assist with any responsible use of TKM-Ebola. The foresight shown by the FDA removes one potential roadblock to doing so."
Click here to read more
This came after the FDA modified the full clinical hold placed on the drug, which enables it to be administered to people sick with the virus.
Excerpt:
Here's what management is said in its 4:45 p.m. ET press release: "[Tekmira] today announced that the U.S. Food & Drug Administration (FDA) has verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola Investigational New Drug Application (IND) to a partial clinical hold. This action enables the potential use of TKM-Ebola in individuals infected with Ebola virus."
"We are pleased that the FDA has considered the risk-reward of TKM-Ebola for infected patients," said Tekmira CEO Mark Murray. "We have been closely watching the Ebola virus outbreak and its consequences, and we are willing to assist with any responsible use of TKM-Ebola. The foresight shown by the FDA removes one potential roadblock to doing so."
Click here to read more
